Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Optaflu in Healthy Adults
NCT01880697Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TIVc in influenza, sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01880697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880697.